FDA grants Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma May 10, 2023
Pivotal Ph 3 INDIGO Trial of vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of PFS and Key Secondary Endpoint of Time to Next Intervention (TTNI) March 31, 2023
FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies March 31, 2023
FDA grants Orphan Drug Designation for the PRMT5 inhibitor JBI-778 for the treatment of Glioblastoma Multiforme (GBM) February 22, 2023
Orphan Drug Designation Granted to Adze-1.17-CD40L for the treatment of Malignant Glioma February 22, 2023
First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma February 1, 2023
Enrollment in Ph 2 Clinical Trial MN-166 (ibudilast) trial in Recurrent and Newly Diagnosed Glioblastoma patients completed January 17, 2023
Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrated Meaningful Responses with Tovorafenib (DAY101) in Pediatric Low-Grade Glioma January 17, 2023
Preliminary Results from Trial of Berubicin for the Treatment of Recurrent GBM announced December 12, 2022
Hemispherian closes the first tranche of series A1 financing round to develop GBM drug November 28, 2022
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Balstilimab in a Ph 2 Study in Primary Glioblastoma Patients October 19, 2022
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor September 28, 2022
